CYP19A1 and osteoporosis: Prolia is approved by the US Food and Drug Administration (FDA) for the following indications: (1) the treatment of postmenopausal women with osteoporosis at high risk for fracture, (2) to increase bone mass in men at high risk for fracture (those with osteoporosis and those receiving androgen deprivation therapy for nonmetastatic prostate cancer), and (3) to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer (Amgen, 2010a).